BRIEF-GlaxoSmithKline CEO plays down generic Advair threat

Wed Feb 5, 2014 8:02am EST

Feb 5 (Reuters) - GlaxoSmithKline Plc CEO Andrew Witty told reporters: * CEO says European respiratory business remains extremely strong despite

"patchy" generics * CEO says new generics to Advair not substitutable in many European markets * CEO says U.S. Advair generics "some distance in the future" * CEO says pleased with Breo start * CEO says nine potential respiratory launches coming through * CEO says long-term trend in emerging markets still upwards, despite

volatility; view remains undimmed * CEO says darapladib and mage-3 drugs remain "intriguing" opportunities * CEO says will file malaria vaccine

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.